2/3상모집 중
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
연구 개요
This study investigates the efficacy and safety of belimumab compared to placebo, in addition to standard therapy, for the treatment of participants with systemic sclerosis associated interstitial lung disease (SSc-ILD). The study will evaluate the effect of belimumab treatment on lung function as well as on extra-pulmonary disease manifestations, including skin thickening and general symptoms, such as fatigue, that impact quality of life (QoL).
- 스폰서
- 리드: GSK
- 적응증
- Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
- 중재
- Belimumab, Placebo
- 목표 등록
- 300명
- 시작일
- 2023-09-13
- 완료(예정)
- 2029-07-12
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.